Endothelial barrier disruption is a pivotal event in the progression of critical illness, leading to increased vascular permeability, tissue edema, and subsequent organ dysfunction. The identification and utilization of biomarkers reflecting endothelial injury have garnered increasing attention for their potential to enhance diagnosis, risk stratification, and therapeutic targeting in critically ill patients. This review synthesizes current evidence regarding established and emerging biomarkers of endothelial barrier disruption, elucidates their mechanistic relevance, and discusses their clinical implications in the management of critical illness.
The vascular endothelium serves as a selectively permeable barrier that regulates the passage of fluids, solutes, and cells between the bloodstream and surrounding tissues. In the context of critical illness—such as sepsis, acute respiratory distress syndrome (ARDS), and trauma—endothelial barrier integrity is frequently compromised, contributing to a cascade of pathophysiological events that culminate in multi-organ dysfunction and increased mortality. Advances in molecular diagnostics have enabled the detection of circulating biomarkers that reflect endothelial barrier disruption, offering new avenues for early detection, prognosis, and therapeutic monitoring in critically ill populations.
Endothelial barrier dysfunction is a common pathological feature across a spectrum of critical illnesses. In sepsis, it contributes to the development of septic shock and organ failure, affecting millions of patients worldwide with high morbidity and mortality rates. ARDS, characterized by non-cardiogenic pulmonary edema, is similarly underpinned by endothelial injury. Epidemiological studies estimate that up to 40% of patients with severe sepsis and over 30% of those with ARDS exhibit significant endothelial barrier disruption, highlighting its substantial burden in intensive care units (ICUs) globally.
The integrity of the endothelial barrier is maintained by intercellular junctions, cytoskeletal elements, and the glycocalyx. Inflammatory mediators released during critical illness—such as cytokines, chemokines, and reactive oxygen species—disrupt these protective structures. Key mechanisms include the degradation of adherens junction proteins (e.g., VE-cadherin), activation of endothelial nitric oxide synthase, and shedding of the glycocalyx. This leads to increased vascular permeability, plasma leakage, and tissue edema, setting the stage for organ dysfunction. The identification of biomarkers that signal these mechanistic events is essential for timely intervention.
Several risk factors predispose individuals to endothelial barrier disruption during critical illness. These include advanced age, pre-existing comorbidities (such as diabetes mellitus, hypertension, and chronic kidney disease), genetic predisposition, and the severity of the inciting illness (e.g., high pathogen load in sepsis). Iatrogenic factors, including aggressive fluid resuscitation and mechanical ventilation with high tidal volumes, further exacerbate endothelial dysfunction. Recognition of these risk factors is vital for both prevention and early detection of complications.
Clinically, endothelial barrier disruption manifests as hypotension, progressive tissue edema, and signs of organ dysfunction—including acute kidney injury, respiratory failure, and altered mental status. Laboratory findings may include hypoalbuminemia, elevated lactate, and abnormal coagulation parameters. These features are often non-specific, underscoring the need for reliable biomarkers to differentiate endothelial injury from other causes of organ dysfunction in the critically ill.
Diagnostic evaluation of endothelial barrier disruption relies on both clinical assessment and laboratory testing. Traditional markers such as lactate and creatinine lack specificity for endothelial injury. In recent years, focus has shifted to endothelial-specific biomarkers, including syndecan-1 (reflecting glycocalyx shedding), angiopoietin-2 (Ang-2), soluble thrombomodulin, and vascular cell adhesion molecule-1 (VCAM-1). Elevated levels of these biomarkers in plasma or serum have been associated with increased vascular permeability, severity of illness, and worse outcomes in sepsis and ARDS. Point-of-care assays and multiplex platforms are being developed to facilitate rapid bedside assessment.
Management strategies for endothelial barrier disruption remain largely supportive, focusing on hemodynamic stabilization, infection control, and organ support. Fluid management is critical; excessive fluid administration can exacerbate capillary leak, while restrictive strategies may worsen hypoperfusion. Adjunctive therapies under investigation include agents that stabilize the endothelial barrier, such as recombinant human thrombomodulin and sphingosine-1-phosphate analogs. Timely identification of endothelial injury through biomarkers may enable targeted interventions and personalized therapy in the future.
Recent research has expanded the repertoire of endothelial biomarkers, incorporating novel candidates such as plasminogen activator inhibitor-1 (PAI-1), endocan, and circulating microRNAs. These molecules provide insights into the dynamic regulation of endothelial function and injury. Therapeutic advances include biologics targeting angiopoietin/Tie2 signaling and agents that restore glycocalyx integrity. Ongoing clinical trials are evaluating the efficacy of these targeted therapies, with biomarker-guided strategies showing promise for improving patient outcomes.
Current international guidelines, including those from the Surviving Sepsis Campaign and the European Society of Intensive Care Medicine, emphasize the importance of early recognition and supportive management of endothelial dysfunction. While routine measurement of endothelial biomarkers is not yet standard practice, guidelines acknowledge their potential for risk stratification and encourage their incorporation into future clinical trials and research protocols.
Biomarkers of endothelial barrier disruption offer valuable tools for understanding, diagnosing, and managing critical illness. Their integration into clinical practice holds promise for advancing precision medicine approaches in the ICU. Continued research into novel biomarkers and targeted therapies is warranted to translate these advances into improved patient outcomes.
1.
A small rise in cancer was observed following the 1986 Chernobyl accident.
2.
CAR-T Induces Deep, Durable Remission in Smoldering Myeloma
3.
Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.
4.
Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial
5.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
1.
Developmental Regulation of Pediatric Red-Cell Production
2.
Exploring the Benefits of Flexible Sigmoidoscopy: A Revolutionary Way to Detect Colorectal Cancer
3.
Robotic Intratumoral Resection for Organ Preservation: Current Evidence and Clinical Implications
4.
Clinical Analysis of Prostate Cancer
5.
Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Signs and Symptoms of Leukemia
2.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
5.
The Role of Hemoglobin in Maintaining Healthy Oxygen Levels
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation